Abstract
Tumor suppressor p53 is essential for checkpoint control in response to a variety of genotoxic stresses. DNA damage leads to phosphorylation on the Ser/Thr-Pro motifs of p53, which facilitates interaction with Pin1, a pSer/pThr-Pro-specific peptidyl prolyl isomerase. Pin1 is required for the timely activation of p53, resulting in apoptosis or cell cycle arrest. To investigate the physiological relationship between Pin1 and p53, we created Pin1−/−p53−/− mice. These p53-deficient mice spontaneously developed lymphomas, mainly of thymic origin, as well as generalized lymphoma infiltration into other organs, including the liver, kidneys and lungs. Ablation of Pin1, in addition to p53, accelerated the thymic hyperplasia, but the thymocytes in these Pin1−/−p53−/− mice did not infiltrate other organs. The thymocytes in 12-week-old Pin1−/−p53−/− mice were CD4−CD8− (double negative) and had significantly higher levels of the intracellular form of Notch1 (NIC) than the thymocytes of p53−/− or wild-type mice. Presenilin-1, a cleavage enzyme for NIC generation from full-length Notch1 was increased in the thymocytes of Pin1−/−p53−/− mice. Pin1 depletion also inhibited the degradation of NIC by proteasomes. These results suggest that both Pin1 and p53 control the normal proliferation and differentiation of thymocytes by regulating the NIC level.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyama H, Shin RW, Uchida C, Kitamoto T, Uchida T . (2005). Pin1 promotes production of Alzheimer's amyloid beta from beta-cleaved amyloid precursor protein. Biochem Biophys Res Commun 336: 521–529.
Amson R, Lassalle JM, Halley H, Prieur S, Lethrosne F, Roperch JP et al. (2000). Behavioral alterations associated with apoptosis and down-regulation of presenilin 1 in the brain of p53-deficient mice. Proc Natl Acad Sci USA 97: 5346–5350.
Appella E, Anderson CW . (2001). Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764–2772.
Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR . (1995). High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5: 931–936.
Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B . (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912–915.
Beverly LJ, Felsher DW, Capobianco AJ . (2005). Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res 65: 7159–7168.
Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S, Bishop JM . (1997). Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 17: 6265–6273.
Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T et al. (1997). Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet 17: 114–118.
Deftos ML, He YW, Ojala EW, Bevan MJ . (1998). Correlating notch signaling with thymocyte maturation. Immunity 9: 777–786.
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal, but susceptible to spontaneous tumours. Nature 356: 215–221.
Fattman CL, An B, Dou QP . (1997). Characterization of interior cleavage of retinoblastoma protein in apoptosis. J Cell Biochem 67: 399–408.
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E et al. (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733–744.
Fowlkes BJ, Robey EA . (2002). A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development. J Immunol 169: 1817–1821.
Fujimori F, Takahashi K, Uchida C, Uchida T . (1999). Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophy Res Commun 265: 658–663.
Haapajärvi T, Kivinen L, Pitknen K, Laiho M . (1995). Cell cycle dependent effects of u.v.-radiation on p53 expression and retinoblastoma protein phosphorylation. Oncogene 11: 151–159.
Hasserjian RP, Aster JC, Davi F, Weinberg DS, Sklar J . (1996). Modulated expression of notch1 during thymocyte development. Blood 88: 970–976.
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7.
Jehn BM, Bielke W, Pear WS, Osborne BA . (1999). Cutting edge: protective effects of notch-1 on TCR-induced apoptosis. J Immunol 162: 635–638.
Katsuda K, Kataoka M, Uno F, Murakami T, Kondo T, Roth JA et al. (2002). Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 21: 2108–2113.
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M et al. (1996). Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85: 721–732.
Kopan R, Schroeter EH, Weintraub H, Nye JS . (1996). Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci USA 93: 1683–1688.
Lai EC . (2002). Notch cleavage: Nicastrin helps Presenilin make the final cut. Curr Biol 12: R200–R202.
Laws AM, Osborne BA . (2004). p53 regulates thymic Notch1 activation. Eur J Immunol 34: 726–734.
Levine AJ . (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE . (1992). Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 89: 9210–9214.
Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, Fujimori F et al. (2002). Loss of Pin1 function in the mouse causes phenotypes resemble cyclin D1-null phenotypes. Proc Natl Acad Sci USA 99: 1335–1340.
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD . (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923–935.
Loubat A, Rochet N, Turchi L, Rezzonico R, Far DF, Auberger P et al. (1999). Evidence for a p23 caspase-cleaved form of p27KIP1 involved in G1 growth arrest. Oncogene 18: 3324–3333.
Lu KP, Hanes SD, Hunter T . (1996). A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380: 544–547.
Lutzker SG, Levine AJ . (1996). A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 2: 804–810.
Lyon MF . (1961). Gene action in the X-chromosome of the mouse (Mus musculus L. Nature 190: 372–373.
Maillard I, Adler SH, Pear WS . (2003). Notch and the immune system. Immunity 19: 781–791.
Müller-Tidow C, Ji P, Diederichs S, Potratz J, Bäumer N, Köhler G et al. (2004). The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 24: 8917–8928.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N et al. (1996). Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 85: 707–720.
Oswald F, Tauber B, Dobner T, Bourteele S, Kostezka U, Adler G et al. (2001). p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol 21: 7761–7774.
Pastorcic M, Das HK . (2000). Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 prorooncogene. J Biol Chem 275: 34938–34945.
Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, Baltimore D . (1996). Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 183: 2283–2291.
Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE et al. (1994). Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9: 603–609.
Radtke F, Wilson A, Mancini SJ, MacDonald HR . (2004). Notch regulation of lymphocyte development and function. Nat Immunol 5: 247–253.
Rastan S . (1994). X chromosome inactivation and the Xist gene. Curr Opin Genet Dev 4: 292–297.
Robey E, Chang D, Itano A, Cado D, Alexander H, Lans D et al. (1996). An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87: 483–492.
Rogel A, Popliker M, Webb CG, Oren M . (1988). p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Biochim Biophys Acta 950: 395–402.
Ronchini C, Capobianco AJ . (2001). Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 21: 5925–5934.
Roperch JP, Alvaro V, Prieur S, Tuynder M, Nemani M, Lethrosne F et al. (1998). Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med 4: 835–838.
Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T . (1995). A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10: 175–180.
Schroeter EH, Kisslinger JA, Kopan R . (1998). Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393: 382–386.
Shaw PE . (2002). Peptidyl-prolyl isomerases: a new twist to transcription. EMBO Rep 3: 521–526.
Slee EA, O'Connor DJ, Lu X . (2004). To die or not to die: how does p53 decide? Oncogene 23: 2809–2818.
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW et al. (1999). Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284: 156–159.
Soussi T . (2000). The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910: 121–139.
Struhl G, Adachi A . (1998). Nuclear access and action of notch in vivo. Cell 93: 649–660.
Takagi N . (1974). Differentiation of X chromosomes in early female mouse embryos. Exp Cell Res 86: 127–135.
Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.
Wahl GM, Carr AM . (2001). The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3: E277–E286. (2002); Erratum in: Nat Cell Biol 4: 328.
Weng AP, Ferrando AA, Lee W, Morris IVJP, Silverman LB, Sanchez-Irizarry C et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269–271.
Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP . (2002). Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 277: 47976–47979.
Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S et al. (2002). The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853–857.
Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G et al. (2002). The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419: 849–853.
Acknowledgements
We thank T Tachikawa, RW Shin and K Takeuchi for supporting the analysis of the histopathology of the mice. We thank A Kondoh and M Suzuki for taking care of the mice. K Fukuchi, T Hasegawa, K Ikeda, D Sato, Y Sano, K Saito, NH Choi-Miura and S Arata for their technical help, and L Ostroff for editorial assistance. This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas (TU), Grant-in-Aid for Scientific Research (TU), and a Special Research Grant-in-Aid for Development of Characteristic Education (KT) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Showa University Grant-in-Aid for Innovative Collaborative Research Projects (KT) and the Center for Interdisciplinary Research Tohoku University for Specially Promoted Research (TU).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Takahashi, K., Akiyama, H., Shimazaki, K. et al. Ablation of a peptidyl prolyl isomerase Pin1 from p53-null mice accelerated thymic hyperplasia by increasing the level of the intracellular form of Notch1. Oncogene 26, 3835–3845 (2007). https://doi.org/10.1038/sj.onc.1210153
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210153
Keywords
This article is cited by
-
Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis
Scientific Reports (2018)
-
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells
Nature Communications (2018)
-
Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4
Oncogene (2017)
-
The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target
Nature Reviews Cancer (2016)
-
The role of Pin1 in the development and treatment of cancer
Archives of Pharmacal Research (2016)